Polymyositis News and Articles

Return to Library

Recent Polymyositis News and Articles

• Report Summarizes Rheumatology Study Findings from Department of Rheumatology
• Researchers from Sichuan University Describe Findings in Dermatology
• Data on Polymyositis Described by Researchers at University of Malaya
• Investigators from China Medical University and Hospital Publish New Data on Cell Biology
• New Dermatomyositis Research Reported from KAN Research Institute
• Research from Kumamoto University Has Provided New Information about Biology
• Studies in the Area of Dermatology Reported from Kanazawa University
• Patent Application Titled \"P38 Inhibitors\" Under Review
• Patent Issued for Pharmaceutical Composition Comprising Racemic Aminopterin

---

Studies from Chonbuk National University School of Medicine in the Area of Dermatomyositis Described

2012 DEC 26 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- Research findings on Skin Diseases and Conditions are discussed in a new report. According to news reporting out of Jeonbuk, South Korea, by NewsRx editors, research stated, "Dermatomyositis (DM) is a systemic autoimmune disorder characterized by the inflammation of skeletal muscles and pathognomonic skin rashes, namely heliotrope rash and Gottron's papules and involvement of other organs. Interstitial lung disease (ILD) seems to be one of the most characteristic manifestations of the lung and associated with increased morbidity and mortality in patients with DM."

Our news journalists obtained a quote from the research from the Chonbuk National University School of Medicine, "Despite DM-associated ILD requires aggressive therapy with cytotoxic agents, the efficacy is questionable in some cases, and more effective and less toxic therapies are needed. Recently, although there have been several reports of successful treatment of refractory case of PM and DM with the TNF-a antagonists, including infliximab and etanercept, there was no enough evidence for DM-associated ILD."

According to the news editors, the research concluded: "We described herein a patient with DM-associated ILD who had poor response to conventional therapies and successfully treated with adalimumab."

For more information on this research see: Successful treatment for conventional treatment-resistant dermatomyositis-associated interstitial lung disease with adalimumab. Rheumatology International, 2012;32(11):3587-90. Rheumatology International can be contacted at: Springer, 233 Spring Street, New York, NY 10013, USA. (Springer - www.springer.com; Rheumatology International - www.springerlink.com/content/0172-8172/)

Our news journalists report that additional information may be obtained by contacting J.K. Park, Division of Rheumatology, Dept. of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine, San 2-20 Geumam-dong, Deokjin-gu, Jeonju, Jeonbuk, 561-180, South Korea.

Publisher contact information for the journal Rheumatology International is: Springer, 233 Spring Street, New York, NY 10013, USA.

Keywords for this news article include: Asia, Antirheumatics, Pharmaceuticals, Drugs, Jeonbuk, Therapy, Adalimumab, South Korea, Polymyositis, Rheumatology, Dermatomyositis, Muscular Diseases, Immunologic Agents, Monoclonal Antibodies, Musculoskeletal Diseases, Interstitial Lung Disease, Respiratory Tract Diseases, Skin Diseases and Conditions.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2012, NewsRx LLC